Novavax, Inc. · NASDAQ:NVAX

Novavax — Q3 2026 Earnings Presentation

30 slides from Novavax's earnings presentation, Nov 5, 2026

  1. Slide 1: Third Quarter 2026 Financial Results & Operational Highlights

    Third Quarter 2026 Financial Results & Operational Highlights November 5, 2026 © 2026 NOVAVAX. All rights reserved. 1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” "target," “g

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures The Company presents the following non-GAAP financial measures in this presentation: Adjusted Total Revenue, Adjusted Licensing, Royalties and Other Revenue, Non-GAAP combined R&D and SG&A expenses, net of partner reimbursement, non-GAAP R&D expenses, net of partner reimb

  4. Slide 4: Q3 2026 Earnings Call Agenda

    Q3 2026 Earnings Call Agenda Welcome 01 Naina Zaman Director, Investor Relations Quarter Overview 02 John C. Jacobs President and Chief Executive Officer Business Development 03 Elaine O’Hara Executive Vice President, Chief Strategy Officer Research and Development 04 Bob Walker, MD Executive Vice P

  5. Slide 5: Three Strategic Pillars Driving Long-Term Value

    Three Strategic Pillars Driving Long-Term Value • Partnering our vaccine technology Maximize value from existing collaborations while building the next generation of licensing opportunities • Targeted and capital-efficient R&D innovation Generate data to support partnering discussions, expand utilit

  6. Slide 6: Novavax Today: A Differentiated Vaccine Technology Company

    Novavax Today: A Differentiated Vaccine Technology Company Q3 2026 & Recent Highlights • In October, Novavax earned a $125M milestone following Sanofi’s Ph3 CIC trial initiation in the EU and Sanofi intends to initiate a U.S. Phase 3 CIC trial in 20271 to support U.S. approval Partnering our vaccine

  7. Slide 7: Business Development Update

    Business Development Update © 2026 NOVAVAX. All rights reserved. 7

  8. Slide 8: Partnership Strategy Focused on Near- and Long-Term Value Creation

    Partnership Strategy Focused on Near- and Long-Term Value Creation Maximize value from existing Build the next generation of collaborations licensing opportunities © 2026 NOVAVAX. All rights reserved. 8

  9. Slide 9: Nuvaxovid 2026-2027 Season

    Nuvaxovid 2026-2027 Season XFG-adapted Nuvaxovid approved in major United States European Union Japan markets The only non-mRNA option in the U.S. Promoting Nuvaxovid in Japan Commercial Direct-to-consumer New ex-U.S. markets World’s third-largest expertise outreach pharmaceutical market Seasoned va

  10. Slide 10: Partnership Value Creation

    Partnership Value Creation Partnerships & Near- to Mid-Term Mid- to Long-Term Collaborations • Achieved $125M milestone for CIC Phase 3 initiation • $225M milestone upon CIC launch in the U.S.1 • Nuvaxovid royalties • Up to $200M in milestones per product plus royalties for each new commercialized a

  11. Slide 11: Research & Development Update

    Research & Development Update © 2026 NOVAVAX. All rights reserved. 11

  12. Slide 12: R&D Innovation Fueling Partnerships

    R&D Innovation Fueling Partnerships Data fuels new partnerships or expansion of existing partnerships with potential for initial upfront payments, development milestones and royalties Generate data for Expand utility of our Advance select partnering Matrix technology innovative vaccine discussions p

  13. Slide 13: Focused R&D: Where We're Building Evidence

    Focused R&D: Where We’re Building Evidence Building evidence for our technology and advancing select vaccine candidates INFECTIOUS DISEASE ONCOLOGY PLATFORM INNOVATION Matrix-M + Licensed Exploratory Preclinical Studies Exploring Further Applications Commercial Vaccines with Novavax Technology • Com

  14. Slide 14: Advancing our Differentiated C. diff Candidate

    Advancing our Differentiated C. diff Candidate C. diff: Novavax Vaccine A life-threatening bacterial infection for Why it Matters Candidate4 at-risk populations* with no approved vaccine today Proven adjuvant to potentially drive broader, more potent Matrix-M® adjuvanted 500k cases of C. diff in the

  15. Slide 15: Financial Results

    Financial Results © 2026 NOVAVAX. All rights reserved. 15

  16. Slide 16: Q3 2026 Financial Update: Progress on Growth Strategy

    Q3 2026 Financial Update Progress on Growth Strategy Partner commercial execution • Quarterly results demonstrate (Sanofi + Takeda + Serum Institute) Q3 2026 Financial Results continued strong execution 41% lower YoY GAAP Combined R&D and SG&A for Q3 2026 • $125M CIC Phase 3 study milestone Sanofi M

  17. Slide 17: Q3 2026 Total Revenue

    Q3 2026 Total Revenue $ in Q3 2026 Highlights millions ($2M) YoY Change 75 $70M $68M 13 o +$12 million higher Product sales (+91% YoY) Product Sales 26 o +$11 million deferred royalty revenue 50 Product Sales o ($42) million lower R&D reimbursement o +$16 million all other YoY changes 57 25 43 Licen

  18. Slide 18: Q3 2026 Financial Results

    Q3 2026 Financial Results (unaudited) ($ in millions, except per share amounts) Q3 2026 Q3 2025 Product sales $ 26 $ 13 Licensing, royalties, and other 43 57 Total revenue 68 70 Cost of sales 23 21 Research and dev elopment 52 98 Selling, general, and administrativ e 24 32 Key drivers of YoY change

  19. Slide 19: Q3 2026 Combined R&D and SG&A Expense

    Q3 2026 Combined R&D and SG&A Expense Significant progress on cost reduction GAAP Q3 YoY trends highlight (41%) continued improvements $ in Non-GAAP millions 130 GAAP Non-GAAP (14%) R&D (47%) (7%) SG&A (25%) (25%) 84 76 72 Total (41%) (14%) R&D R&D Non-GAAP combined R&D and SG&A is net of partner re

  20. Slide 20: Full Year 2026 Revenue Framework & Expense Guidance

    Full Year 2026 Revenue Framework & Expense Guidance Full Year 2026 Revenue Framework Full Year 2026 Full Year 2026 $ in millions (as of Nov 5, 2026) (as of Aug 6, 2026) Raising range Nuvaxovid Product Sales1 $40 - $50 $35 - $45 for FY 2026 Framework Adjusted Supply Sales2 $50 - $60 $45 - $55 Sanofi

  21. Slide 21: Full Year 2026 Revenue Framework Footnotes (See Slide 20)

    Full Year 2026 Revenue Framework Footnotes (See Slide 20) Revenue Categories Revenue Framework Footnotes Nuvaxovid Product Sales1 $40 million to $50 million in Nuvaxovid Product Sales by Novavax under existing APA and commercial agreements. Expect to exclude from the 2027 Revenue Framework. Adjusted

  22. Slide 22: Non-GAAP Combined R&D and SG&A Expense Guidance

    Non-GAAP Combined R&D and SG&A Expense Guidance1,2,3,4 Targeting a >$200M and >50% $ in decrease as partner and APA millions Novavax path to achieve 408 support activities are completed a lean and agile 400 operating model 325 o Complete partner and APA ~$125M Partner 225 support activities and APA

  23. Slide 23: Financial Objectives and Value Creation

    Financial Objectives and Value Creation Drive revenue from a diversified set of license partners and products to deliver long-term cash flow growth Targeted and capital-efficient R&D investment to drive long-term value creation • Generate a library of data to enable Matrix-M partnering • Expand util

  24. Slide 24: Closing Remarks

    Closing Remarks © 2026 NOVAVAX. All rights reserved. 24

  25. Slide 25: Novavax 2026 & Beyond

    Novavax 2026 & Beyond YEAR-TO-DATE HIGHLIGHTS POTENTIAL FUTURE MILESTONES & CATALYSTS ✓ Novavax earned $125M milestone as Sanofi launches • Sanofi's initiation of a U.S. Phase 3 CIC Phase 3 CIC vaccine trial in Europe vaccine trial in 2027 to support U.S. approval • Nuvaxovid manufacturing technolog

  26. Slide 26: Q&A

    Q&A © 2026 NOVAVAX. All rights reserved. 26

  27. Slide 27: Appendix

    Appendix © 2026 NOVAVAX. All rights reserved. 27

  28. Slide 28: Q3 2026 and Year to Date 2026 Total Revenue

    Q3 2026 and Year to Date 2026 Total Revenue Third Quarter Year to Date $ in millions Q3 2026 Q3 2025 Change % FY 2026 FY 2025 Change % Product Sales1 $ 26 $ 13 $ 12 91% $ 87 $ 646 $ (559) (87%) Sanofi 2 19 48 (30) (61%) 103 288 (185) (64%) Pfizer 0 0 0 NM 30 0 30 100% Takeda 7 6 1 14% 8 34 (25) (75%

  29. Slide 29: Reconciliation of GAAP to Non-GAAP Financial Results

    Reconciliation of GAAP to Non-GAAP Financial Results Twelve Months (unaudited) Three Months Ended Nine Months Ended Ended ($ in millions) September 30, September 30, December 31, 2026 2025 2026 2025 2025 R&D Expenses $52.4 $98.3 $218.6 $266.4 $342.3 Adjustments: R&D Reimbursement 3.8 45.8 54.1 63.6

  30. Slide 30: © 2026 NOVAVAX. All rights reserved.

    © 2026 NOVAVAX. All rights reserved. 30

Novavax — Q3 2026 Earnings Presentation on 6ix